Objectives Board of Directors Advisory Board Leadership Sponsors
CIB2012 CIB2011 CIB2010 ICTM 2011
Executive Committee Education Committee International Collaboration Committee Communication Committee Membership Committee
Cellular & Molecular Medicine Applied Immunology Molecular Imaging Regenerative medicine Drug development and discovery Biomaterials & Clinical Application Omics Science
ISTM Newsletter Journals
Certification and Diplomate Program Short Term Training Abroad Long Term Abroad Training Fellowship Observer-ships Abroad
Conferences Travel Grants Travel Grants for Short Term Training Abroad Travel Fellowship for Long Term Abroad Training Observer-ships Abroad Grants Excellent in Translational Medicine Award Research Grants
News Home>>News

Dr Nakase et al described eicosapentaenoic Acid as long-term secondary prevention

It is sometimes difficult to choose anti-thrombotic agents for secondary prevention in stroke patients at high bleeding risk. Recently, Eicosapentaenoic Acid (EPA) was reported to reduce the recurrence of stroke in hypercholesterolemic patients without increasing hemorrhagic risk. In this study, we investigated the features of recurrent stroke patients during EPA medication as secondary stroke prevention.

Following the approval of the ethical committee, stroke patients in the outpatient clinic were consecutively screened and patients who continuously take EPA were enrolled in this study (n = 71, average age 69.7 yo). Blood sample data was adopted from the latest visit or the admission at the stroke recurrence. According to the previous stroke history, all patients were classified into the hemorrhagic stroke (HS) group (n = 10) and the ischemic stroke, including asymptomatic infarction, (IS) group (n = 61).

Any stroke recurrence was not observed in the HS group. Whereas, ischemic stroke recurrence was observed in 6 patients in the IS group, although there was no hemorrhagic stroke recurrence. Recurrent stroke patients showed the higher serum level of cholesterol or the renal dysfunction. The stroke subtype of patients were 2 embolic strokes, 3 atherothrombotic infarctions (two were compromised with renal failure and one had insufficient amount of EPA) and one lacunar infarction (who showed high triglyceride level).

Hemorrhagic stroke was not occurred in our observation of EPA prescribed patients. The clinical features of recurrent stroke patients were the existing complications of dyslipidemia and renal dysfunction.

More information on the article can be found in the journal of Clinical & Translational Medicine (www.clintransmed.com)

Sponsors

Copyright © 2011 istmed.org All rights Reserved.  International Society for Translational Medicine

Technical support: weicheng